Elite Pharmaceuticals Inc (ELTP) stock
ELTPOTCPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/30
$0.25−0.00 (-1.37%)
Close on Oct 19, 2026Market cap $283.02MP/E 5.0Yield –
Elite Pharmaceuticals free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Elite Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was $17.53M, down 2.8% year over year. For fiscal 2026 it was $22.82M, up 291.4% from the year before. The highest annual figure on record is $22.82M in fiscal 2026.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $22.82M | +291.4% |
| FY2025 | Mar 31, 2025 | $5.83M | – |
| FY2024 | Mar 31, 2024 | -$4.04M | – |
| FY2023 | Mar 31, 2023 | -$2.40M | -139.9% |
| FY2022 | Mar 31, 2022 | $6.01M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | $9.26M | -36.4% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $8.75M | +176.5% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | -$5.48M | – |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $5.00M | +266.5% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $14.56M | +515.3% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $3.16M | +86.6% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | -$1.06M | -143.7% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $1.36M | – |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $2.37M | – |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $1.70M | – |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $2.43M | – |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | -$568.59K | – |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | -$3.61M | – |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | -$652.11K | – |
See a number that looks wrong?